Nanomaterials: Versatile Drug Carriers for Nanomedicine
289
38. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson
M (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound
doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085–2091
39. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, Nel AE (2010) Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and p-glycoprotein siRNA to overcome
drug resistance in a cancer cell line. ACS Nano 4:4539–4550. https://doi.org/10.1021/nn1
00690m
40. Adams JM, Cory S (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
Curr Opin Immunol 19:488–496
41. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, He H (2009) Co-delivery
of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy
of chemotherapy in multidrug-resistant cancer cells. Small 5:2673–2677. https://doi.org/10.
1002/smll.200900621
42. Chen S, Zhao D, Li F, Zhuo RX, Cheng SX (2012) Co-delivery of genes and drugs with
nanostructured calcium carbonate for cancer therapy. RSC Adv 2:1820–1826
43. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, Lee S, Park JH, Park RW, Kim IS, Choi
K (2010) Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous
diagnosis, drug delivery, and therapeutic monitoring. J Control Release 146:219–227
44. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, Huh YM, Haam S (2007) Multifunctional
magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on
breast cancer. Angew Chemie Int Ed 46:8836–8839. https://doi.org/10.1002/anie.200703554
45. Medarova Z, Pham W, Farrar C, Petkova V, Moore A (2007) In vivo imaging of siRNA
delivery and silencing in tumors. Nat Med 13:372–377
46. Guo S, Qiao Y, Wang W, He H, Deng L, Xing J, Xu J, Liang XJ, Dong A (2010)
Poly (ε-caprolactone)-graft-poly (2-(N, N-dimethylamino) ethyl methacrylate) nanoparticles:
pH dependent thermo-sensitive multifunctional carriers for gene and drug. J Mater Chem
20:6935–6941
47. Ruoslahti E, Bhatia S, Sailor M (2010) Targeting of drugs and nanoparticles to tumors. J Cell
Biol 188:759–768
48. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle
systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626
49. Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. Annu Rev Cell
Dev Biol 27:563–584. https://doi.org/10.1146/annurev-cellbio-092910-154002
50. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, Croix BS (2007) Genes that
distinguish physiological and pathological angiogenesis. Cancer Cell 11:539–554
51. Gullotti E, Yeo Y (2009) Extracellularly activated nanocarriers: a new paradigm of tumor
targeted drug delivery. Mol Pharm 6:1041–1051
52. Dilnawaz F, Singh A, Mohanty C, Sahoo SK (2010) Dual drug loaded superparamagnetic
iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694–3706
53. Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, Pignol JP, Reilly RM
(2012) Role of antibody-mediated tumor targeting and route of administration in nanoparticle
tumor accumulation in vivo. Mol Pharm 9:2168–2179
54. Adolphi NL, Butler KS, Lovato DM, Tessier TE, Trujillo JE, Hathaway HJ, Fegan DL,
Monson TC, Stevens TE, Huber DL, Ramu J, Milne ML, Altobelli SA, Bryant HC, Larson
RS, Flynn ER (2012) Imaging of Her2-targeted magnetic nanoparticles for breast cancer
detection: comparison of SQUID-detected magnetic relaxometry and MRI. Contrast Media
Mol Imaging 7:308–319. https://doi.org/10.1002/cmmi.499
55. Qian ZM, Tang PL (1995) Mechanisms of iron uptake by mammalian cells. Biochim Biophys
Acta (BBA)-Molecular Cell Res 1269:205–214
56. Li X, Ding L, Xu Y, Wang Y, Ping Q (2009) Targeted delivery of doxorubicin using stealth
liposomes modified with transferrin. Int J Pharm 373:116–123
57. Fonseca C, Moreira JN, Ciudad CJ, de Lima MCP, Simoes S (2005) Targeting of sterically
stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur J Pharm Biopharm 59:359–
366
289
38. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson
M (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound
doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085–2091
39. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, Nel AE (2010) Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and p-glycoprotein siRNA to overcome
drug resistance in a cancer cell line. ACS Nano 4:4539–4550. https://doi.org/10.1021/nn1
00690m
40. Adams JM, Cory S (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential.
Curr Opin Immunol 19:488–496
41. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T, He H (2009) Co-delivery
of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy
of chemotherapy in multidrug-resistant cancer cells. Small 5:2673–2677. https://doi.org/10.
1002/smll.200900621
42. Chen S, Zhao D, Li F, Zhuo RX, Cheng SX (2012) Co-delivery of genes and drugs with
nanostructured calcium carbonate for cancer therapy. RSC Adv 2:1820–1826
43. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, Lee S, Park JH, Park RW, Kim IS, Choi
K (2010) Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous
diagnosis, drug delivery, and therapeutic monitoring. J Control Release 146:219–227
44. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, Huh YM, Haam S (2007) Multifunctional
magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on
breast cancer. Angew Chemie Int Ed 46:8836–8839. https://doi.org/10.1002/anie.200703554
45. Medarova Z, Pham W, Farrar C, Petkova V, Moore A (2007) In vivo imaging of siRNA
delivery and silencing in tumors. Nat Med 13:372–377
46. Guo S, Qiao Y, Wang W, He H, Deng L, Xing J, Xu J, Liang XJ, Dong A (2010)
Poly (ε-caprolactone)-graft-poly (2-(N, N-dimethylamino) ethyl methacrylate) nanoparticles:
pH dependent thermo-sensitive multifunctional carriers for gene and drug. J Mater Chem
20:6935–6941
47. Ruoslahti E, Bhatia S, Sailor M (2010) Targeting of drugs and nanoparticles to tumors. J Cell
Biol 188:759–768
48. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle
systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626
49. Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. Annu Rev Cell
Dev Biol 27:563–584. https://doi.org/10.1146/annurev-cellbio-092910-154002
50. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, Croix BS (2007) Genes that
distinguish physiological and pathological angiogenesis. Cancer Cell 11:539–554
51. Gullotti E, Yeo Y (2009) Extracellularly activated nanocarriers: a new paradigm of tumor
targeted drug delivery. Mol Pharm 6:1041–1051
52. Dilnawaz F, Singh A, Mohanty C, Sahoo SK (2010) Dual drug loaded superparamagnetic
iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694–3706
53. Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, Pignol JP, Reilly RM
(2012) Role of antibody-mediated tumor targeting and route of administration in nanoparticle
tumor accumulation in vivo. Mol Pharm 9:2168–2179
54. Adolphi NL, Butler KS, Lovato DM, Tessier TE, Trujillo JE, Hathaway HJ, Fegan DL,
Monson TC, Stevens TE, Huber DL, Ramu J, Milne ML, Altobelli SA, Bryant HC, Larson
RS, Flynn ER (2012) Imaging of Her2-targeted magnetic nanoparticles for breast cancer
detection: comparison of SQUID-detected magnetic relaxometry and MRI. Contrast Media
Mol Imaging 7:308–319. https://doi.org/10.1002/cmmi.499
55. Qian ZM, Tang PL (1995) Mechanisms of iron uptake by mammalian cells. Biochim Biophys
Acta (BBA)-Molecular Cell Res 1269:205–214
56. Li X, Ding L, Xu Y, Wang Y, Ping Q (2009) Targeted delivery of doxorubicin using stealth
liposomes modified with transferrin. Int J Pharm 373:116–123
57. Fonseca C, Moreira JN, Ciudad CJ, de Lima MCP, Simoes S (2005) Targeting of sterically
stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur J Pharm Biopharm 59:359–
366